enfinity® Paraxanthine

Evidence Level
Limited
3 Clinical Trials
4 Documented Benefits
2/5 Evidence Score

enfinity® is a branded, pharmaceutical-grade form of paraxanthine, the primary metabolite of caffeine in the human body. After ingesting caffeine, roughly 80% is metabolized to paraxanthine by hepatic CYP1A2, and two small branded crossover trials, in 12 and 13 healthy adults, have tested paraxanthine against placebo on cognitive tasks. Less jitter, less impact on heart rate, and a shorter half-life are comparisons with caffeine that neither of those trials measured. Acute and short-term dosing at 50-200 mg has been examined for attention, memory, and reaction time, and not every measure reached statistical significance. The safety toxicology cited on this page was conducted in Wistar rats, not in people, and covered acute, 28-day subacute, and 90-day subchronic oral dosing. As a newer category, enfinity® is most often used at 100-200 mg in cognitive and pre-workout formulas.

Studied Dose 100-200 mg per serving; 50, 100, and 200 mg evaluated in the one dose-response crossover trial cited here, in 12 participants.
Active Compound Paraxanthine (1,7-dimethylxanthine), the primary methylxanthine metabolite of caffeine, supplied as a high-purity powder. "Pharmaceutical grade" is a supplier marketing term with no regulatory definition for dietary ingredients.

Benefits

Supports Cognitive Performance

Two small double-blind, placebo-controlled crossover trials, one in 12 healthy adults and one in 13, reported improvements on some measures of reaction time, attention, and short-term memory at 100-200 mg compared with placebo. Not every measure moved: Sternberg Task 4-Letter reaction time did not reach significance in the dose-response trial (p=0.06), and several Sternberg variables in the 200 mg trial were trends that fell short of significance.

Helps Sustain Attention Under Load

In the 200 mg crossover trial in 13 adults, sustained attention and short-term memory reaction times improved and Berg-Wisconsin Card Sorting Task errors fell (p=0.04) compared with placebo. No cited trial compared paraxanthine head to head with caffeine, so no equivalence to a moderate caffeine dose should be inferred from this page.

Post-Exercise Cognition: Uncited on This Page

A trial comparing paraxanthine with caffeine after a 10-km run has been described for this ingredient, but it is not among the references listed on this page. The claim of favorable effects on prefrontal cortex function is therefore uncited here and should be treated as unverified until a source is attached.

Caffeine Metabolite With a Distinct Profile

As the primary metabolite of caffeine, paraxanthine shares the adenosine-antagonism mechanism that drives focus and arousal, while its half-life and receptor binding profile differ from caffeine's. Neither cited trial compared subjective effects such as jitter or mood against caffeine, so a smoother feel is not something the evidence on this page can support.

Mechanism of action

1

Adenosine Receptor Antagonism

Paraxanthine competitively blocks adenosine A1 and A2A receptors in the central nervous system, reducing the sleep-promoting and fatigue-signaling effects of adenosine. This is receptor pharmacology: the cited human trials measured performance on cognitive tests, not wakefulness, energy, or fatigue.

2

Dopamine and Catecholamine Signaling

Through A2A receptor blockade, paraxanthine indirectly enhances dopaminergic signaling in regions associated with motivation, attention, and reward — a mechanism shared with caffeine.

3

Lipolysis and Bioenergetic Effects

Like other methylxanthines, paraxanthine increases cAMP and can promote lipolysis in laboratory settings. No study cited on this page measured lipolysis, fuel use, or exercise performance in people taking paraxanthine.

Clinical trials

1
Dose-Response of Paraxanthine on Cognition

Double-blind, placebo-controlled, crossover trial; 50, 100, and 200 mg paraxanthine vs placebo with 7-day daily intake assessments

12 healthy young adults, mean age 22.7 years

Acute paraxanthine ingestion was associated with improvements on several cognitive measures, most consistently at the 100-200 mg doses, but Sternberg Task 4-Letter reaction time did not reach significance (p=0.06). With 12 participants in a crossover design this is a preliminary signal rather than a settled effect. Seven-day daily ingestion was reported to be free of clinically significant side effects.

2
Acute 200 mg Paraxanthine and Cognition

Double-blind, placebo-controlled, crossover trial; single 200 mg paraxanthine vs placebo on cognitive and attentional tasks

13 healthy male and female participants in total

In 13 participants, a single 200 mg dose reduced Berg-Wisconsin Card Sorting Task errors (p=0.04) and improved sustained attention and short-term memory reaction times compared with placebo. Some Sternberg Task variables showed trends that did not reach significance. No adverse events were reported.

3
Paraxanthine vs Caffeine After Endurance Running

Double-blind, randomized, crossover trial; 200 mg paraxanthine vs 200 mg caffeine vs placebo combinations following a 10-km run. This trial is not cited in the reference list on this page

12 trained runners, as reported in a source not cited on this page

Paraxanthine was reported to improve cognitive function after the 10-km run more than caffeine, with no additive benefit from co-ingestion. Because no reference for this trial is listed on this page, these results are uncited here and the conclusion of a distinct nootropic action should not be taken as established.

Side effects and drug interactions

Common Potential side effects

Generally well tolerated in trials at 50-200 mg; mild headache or jitteriness possible at higher doses.
May cause GI upset, especially on an empty stomach.
Stimulant cross-tolerance and sleep disruption are possible if taken late in the day.
Long-term human safety data beyond short trial durations remain limited.

Important Drug interactions

Theoretical additive effects with caffeine and other stimulants — combine cautiously.
CYP1A2 inhibitors and inducers may modify paraxanthine pharmacokinetics.
Discuss use with a clinician if you take antiarrhythmics or stimulant medications.

Frequently asked questions about enfinity® Paraxanthine

What is enfinity Paraxanthine?

enfinity® is a branded, pharmaceutical-grade form of paraxanthine, the primary metabolite of caffeine in the human body. After ingesting caffeine, roughly 80% is metabolized to paraxanthine by hepatic CYP1A2, and two small branded crossover trials, in 12 and 13 healthy adults, have tested paraxanthine against placebo o…

What is enfinity Paraxanthine used for?

enfinity Paraxanthine is researched primarily for Cognitive. Two small double-blind, placebo-controlled crossover trials, one in 12 healthy adults and one in 13, reported improvements on some measures of reaction time, attention, and short-term memory at 100-200 mg compared with placebo.

What is the recommended dosage of enfinity Paraxanthine?

The clinically studied dose is 100-200 mg per serving; 50, 100, and 200 mg evaluated in the one dose-response crossover trial cited here, in 12 participants. Always follow the product label and check with a healthcare provider for personal advice.

Is enfinity Paraxanthine safe, and does it have side effects?

For most healthy adults, enfinity Paraxanthine is well tolerated at studied doses. Reported effects can include: Generally well tolerated in trials at 50-200 mg; mild headache or jitteriness possible at higher doses. May cause GI upset, especially on an empty stomach. It may also interact with some medications. enfinity Paraxanthine is not right for everyone, so check with a healthcare provider first if you are pregnant or breastfeeding, have a medical condition, or take prescription medication.

Does enfinity Paraxanthine interact with any medications?

Possible interactions include: Theoretical additive effects with caffeine and other stimulants — combine cautiously. CYP1A2 inhibitors and inducers may modify paraxanthine pharmacokinetics. If you take prescription medication, check with a pharmacist or doctor before using it.

How strong is the scientific evidence for enfinity Paraxanthine?

NutraSmarts rates the evidence for enfinity Paraxanthine as Limited (2 out of 5). It is backed by 3 clinical trials and 3 cited references summarized on this page. A higher rating reflects more, larger, and better-designed human studies.

References(3 citations)

Evidence ratings on NutraSmarts are based on the totality of human clinical research, with emphasis on randomized controlled trials, meta-analyses, and systematic reviews. The references below directly support claims made throughout this page.

  1. Xing D, Yoo C, Gonzalez D, et al. Dose-response of paraxanthine on cognitive function: a double blind, placebo controlled, crossover trial. Nutrients. 2021;13(12):4478. doi: 10.3390/nu13124478.PubMedUsed to support: Crossover trial in 12 healthy young adults, mean age 22.7 years, of 50/100/200 mg paraxanthine reporting cognitive improvements (most consistent at 100-200 mg), a non-significant Sternberg 4-Letter reaction time result (p=0.06), and tolerability over 7-day daily intake.
  2. Yoo C, Xing D, Gonzalez D, et al. Acute paraxanthine ingestion improves cognition and short-term memory and helps sustain attention in a double-blind, placebo-controlled, crossover trial. Nutrients. 2021;13(11):3980. doi: 10.3390/nu13113980.PubMedUsed to support: Crossover trial of single 200 mg paraxanthine in 13 adults showing improved cognitive function, short-term memory, and sustained attention vs placebo.
  3. Purpura M, Jäger R, Falk M. An assessment of mutagenicity, genotoxicity, acute-, subacute and subchronic oral toxicity of paraxanthine (1,7-dimethylxanthine). Food Chem Toxicol. 2021;158:112579. doi: 10.1016/j.fct.2021.112579.PubMedUsed to support: Animal toxicology in Wistar rats: acute, 28-day subacute, and 90-day subchronic oral dosing plus mutagenicity and genotoxicity testing, reported with no genotoxicity or mutagenicity signal. No human outcome was measured, and no specific no-observed-adverse-effect level is quoted here.